SCHEMBL3263294

SCHEMBL3263294

CCCCCC(=O)c1cc2ccccc2nc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HTT P42858 3/20 0.47
ATM Q13315 1/20 0.43
TLR8 Q9NR97 3/20 0.43
FAAH O00519 2/20 0.43
MAPT P10636 1/20 0.43
DAGLA Q9Y4D2 1/20 0.43
CES1 P23141 1/20 0.43
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
RAB9A P51151 2/20 0.42
KMT2A Q03164 1/20 0.42
MAP4K4 O95819 1/20 0.41
CDK1 P06493 1/20 0.41
CDK2 P24941 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
LIMK1 P53667 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19876966 0.80 FAAH (0.43) SMN1; SMN2ALDH1A1HTTTLR8FAAH
SCHEMBL19890270 0.79 FAAH (0.42) SMN1; SMN2KDM4EALDH1A1HTTTLR8
SCHEMBL19876790 0.78 NPSR1 (0.47) SMN1; SMN2KDM4EALDH1A1HTTATM
SCHEMBL19876763 0.77 KDM4E (0.49) KDM4EALDH1A1HTTTLR8FAAH
SCHEMBL29145018 0.77 FAAH (0.57) FAAHDAGLACES1
SCHEMBL19876762 0.77 KDM4E (0.49) KDM4EALDH1A1HTTTLR8FAAH
SCHEMBL19890145 0.77 FAAH (0.54) FAAHDAGLACES1
SCHEMBL1767933 0.76 FAAH (0.56) TLR8FAAHDAGLACES1
SCHEMBL3144090 0.76 KDM4E (0.55) SMN1; SMN2KDM4EALDH1A1HTTATM
SCHEMBL287359 0.76 OXER1 (0.49) KDM4EALDH1A1HTTTLR8DAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-08-07 US claimed
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-02-18 US claimed
US-11161824-B2 Heterocyclic lipoxin analogs and uses thereof UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2021-11-02 US disclosed
US-11161824-B2 Heterocyclic lipoxin analogs and uses thereof UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2021-11-02 US disclosed
EP-3500559-B1 HETEROCYCLIC LIPOXIN ANALOGS AND USES THEROF UNIV COLLEGE DUBLIN NAT UNIV IRELAND DUBLIN (IE) 2021-06-16 EP disclosed
EP-3500559-B1 HETEROCYCLIC LIPOXIN ANALOGS AND USES THEROF UNIV COLLEGE DUBLIN NAT UNIV IRELAND DUBLIN (IE) 2021-06-16 EP disclosed
US-20210053927-A1 Heterocyclic Lipoxin Analogs and Uses Thereof UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2021-02-25 US disclosed
US-20210053927-A1 Heterocyclic Lipoxin Analogs and Uses Thereof UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2021-02-25 US disclosed
EP-3500559-A1 HETEROCYCLIC LIPOXON ANALOGS AND USES THEROF University College Dublin (IE) 2019-06-26 EP disclosed
WO-2018033642-A9 HETEROCYCLIC LIPOXIN ANALOGS AND USES THEREOF UNIVERSITY COLLEGE DUBLIN (IE) 2018-10-18 WO disclosed
WO-2018033642-A1 HETEROCYCLIC LIPXON ANALOGS AND USES THEROF UNIVERSITY COLLEGE DUBLIN (IE) 2018-02-22 WO disclosed
WO-2018033642-A1 HETEROCYCLIC LIPXON ANALOGS AND USES THEROF UNIVERSITY COLLEGE DUBLIN (IE) 2018-02-22 WO disclosed
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-08-07 US disclosed
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C SMN1; SMN2 1722/4885KDM4E 3028/4885ALDH1A1 1897/4885
US-11161824-B2 Heterocyclic lipoxin analogs and uses thereof LTB4R2, ALOX12, ALOX15B SMN1; SMN2 3676/4885KDM4E 1736/4885ALDH1A1 1306/4885
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C SMN1; SMN2 1722/4885KDM4E 3028/4885ALDH1A1 1897/4885
US-20210053927-A1 Heterocyclic Lipoxin Analogs and Uses Thereof LTB4R2, ALOX12, ALOX15B SMN1; SMN2 3676/4885KDM4E 1736/4885ALDH1A1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.